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Accumulation of the microtubule-associated protein tau into neurofibrillary lesions is a pathological consequence of several neurode-
generative diseases, including Parkinson’s disease and Alzheimer’s disease. Hereditary mutations in the MAPT gene were shown to
promote the formation of structurally distinct tau aggregates in patients that had a parkinsonian-like clinical presentation. Whether tau
aggregates themselves or the soluble intermediate species that precede their aggregation are neurotoxic entities in these disorders has yet
to be resolved; however, recent in vivo evidence supports the latter. We hypothesized that depletion of CHIP, a tau ubiquitin ligase, would
lead to an increase in abnormal tau. Here, we show that deletion of CHIP in mice leads to the accumulation of non-aggregated, ubiquitin-
negative, hyperphosphorylated tau species. CHIP / mice also have increased neuronal caspase-3 levels and activity, as well as caspase-
cleaved tau immunoreactivity. Overexpression of mutant (P301L) human tau in CHIP / mice is insufficient to promote either argyr-
ophilic or “pre-tangle” structures, despite marked phospho-tau accumulation throughout the brain. These observations are supported in
postdevelopmental studies using RNA interference for CHIP (chn-1) in Caenorhabditis elegans and cell culture systems. Our results
demonstrate that CHIP is a primary component in the ubiquitin-dependent degradation of tau. We also show that hyperphosphorylation
and caspase-3 cleavage of tau both occur before aggregate formation. Based on these findings, we propose that polyubiquitination of tau
by CHIP may facilitate the formation of insoluble filamentous tau lesions.
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Introduction
The most prevalent form of age-associated dementia, Alzhei-
mer’s disease (AD), is histologically characterized by the forma-
tion of neurofibrillary tangles (NFTs) composed of the
microtubule-associated protein tau, accompanied by extracellu-
lar formation of amyloid plaques composed of the amyloid 
peptide (A); however, it is the tau pathology in AD that most
closely correlates with neuronal loss (Gomez-Isla et al., 1997) and
clinical dementia (Grundke-Iqbal et al., 1986; Ihara et al., 1986;
Crystal et al., 1988). The discovery that mutations in the gene for
tau (MAPT) cause FTDP-17 (frontotemporal dementia with
parkinsonism-linked to chromosome 17) (Hutton et al., 1998;
Spillantini et al., 1998), which is associated with tau aggregates
within neurons and glia, provided conclusive evidence that ab-
normalities in tau were sufficient to produce neurodegeneration
independent of A. The accumulation of aberrant tau species is
also the primary histopathological hallmark of several neurode-
generative disorders, including corticobasal degeneration, pro-
gressive supranuclear palsy, and argyrophilic grain disease (Ish-
izawa et al., 2003; Wszolek et al., 2004; Zimprich et al., 2004).
Recent work demonstrated that suppression of mutant tau
expression in transgenic mice at an age when NFT pathology and
memory deficits were manifest resulted in rescue of cognitive
defects and neuronal loss without altering neurofibrillary pathol-
ogy (Santacruz et al., 2005). This suggested that formation of tau
aggregates might not be the primary mechanism linking tau pa-
thology to neuronal death, but rather the soluble intermediates
that culminate in NFT formation. Perhaps over-burdened or
malfunctioning protein degradative systems, which would nor-
mally remove these toxic intermediate tau species (An et al., 2003;
Layfield et al., 2003), are forced to partition tau into aggregates as
an adaptive cellular response in terminally differentiated neurons
to prevent their ill effects.
A role for the ubiquitin proteasome system (UPS) in the re-
moval of aberrant tau species was suggested by studies demon-
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strating that proteasome-dependent degradation of constitutive
heat shock protein 70 (Hsc70)-bound phospho-tau was specifi-
cally facilitated by the cochaperone CHIP (C terminus of the
Hsc70-interacting protein) through direct ubiquitin ligase activ-
ity (Petrucelli et al., 2004; Shimura et al., 2004). Very recently, it
was demonstrated that aggregated tau species isolated from AD
brain tissue by immunoprecipitation with a conformation-
specific antibody were, in fact, polyubiquitinated at lysine resi-
dues near or within the microtubule binding region (Cripps et al.,
2006), suggesting that these sites are not only critical for tau
degradation but perhaps have a role in microtubule dynamics.
These findings correlate well with the recent finding that CHIP
levels were elevated in AD samples relative to control tissue (Sa-
hara et al., 2005), further suggesting that CHIP plays an impor-
tant role in mature tangle formation. Additionally, a recent pro-
teomic study identified HSP70, HSP90, and tau as CHIP binding
partners (Bomar et al., 2003; Grelle et al., 2006). Here, we have
characterized the effect of CHIP deletion on endogenous mouse
tau as well as overexpressed mutant (P301L) human tau (Lewis et
al., 2000; Dai et al., 2003). We have determined that CHIP is
critical for degradation of phosphorylated tau species and may
play a role in the formation of neurofibrillary pathology.
Materials and Methods
Antibodies for Western blotting. The antibodies used were as follows: rab-
bit polyclonal CHIP antibody (1:1000) (Petrucelli et al., 2004); rabbit
polyclonal total tau and ubiquitin antibodies (1:1000; Dako, Carpinteria,
CA); Tau5 and Tau-C3 [mouse monoclonal total tau antibody (1:1000)
and a monoclonal antibody recognizing tau cleaved by caspase-3 at Asp
421, respectively; provided by L. Binder, Northwestern University School
of Medicine, Chicago, IL]; CP13 phospho-tau S202/T205 monoclonal
antibody and PHF-1 phospho-tau S396/S404 monoclonal antibody (1:
100; provided by P. Davies, Albert Einstein College of Medicine, Bronx,
NY); 12E8 phospho-tau S262/356 monoclonal antibody (1:1000; pro-
vided by P. Seubert, Elan Pharmaceuticals, San Francisco, CA) (Seubert
et al., 1995; Sun et al., 2003); glyceraldehyde-3-phosphate dehydrogenase
(GAPDH) monoclonal antibody (1:5000; Biodesign International, Ken-
nebunkport, ME); HSP70 monoclonal antibody (1:1000; StressGen Bio-
technologies, Victoria, British Columbia, Canada); capase-3 and cleaved
caspase-3 monoclonal antibodies (1:1000; Cell Signaling, Beverly, MA);
-adrenergic receptor monoclonal antibody (1:1000; Abcam, Cam-
bridge, MA); -synuclein (1:500; LB509; Zymed, San Francisco, CA);
and HRP-conjugated secondary antibodies (1:5000; Jackson Immu-
noResearch, West Grove, PA).
Cell culture and small interfering RNA transfections. The mouse
Neuro-2a neuroblastoma cell line (N2A) was grown in Opti-Mem plus
10% FBS and passaged every 3–5 d based on 90% confluence. For CHIP
small interfering RNA (siRNA) transfections, siRNA was predesigned by
Ambion (Austin, TX) for accession number NM_019719; the sense se-
quence was 5-GGAGCAGCGACUCAACUUUtt-3. The final siRNA
(CHIP or a validated negative control siRNA; Ambion) concentration
per well was 30 nM in Opti-Mem with 2 l of siPORT Amine transfection
reagent (Ambion) used per well. This mixture was incubated in a final
volume of 200 l for 15 min and added to 40 –50% confluent N2A cells in
6-well dishes for a final in-well volume of 2.5 ml. For optimal knockdown
of protein levels, the cells were incubated in the presence of the transfec-
tion reaction for 24 h and replaced with fresh media for an additional
48 h. Cells were harvested for subsequent Western blot analysis in lysis
buffer containing 50 mM Tris-HCl, pH 7.4, 1 M NaCl, 0.1% Triton-X, 5
mM EDTA plus 1% SDS, PMSF, and both a protease and phosphatase
inhibitor mixture.
Caenorhabditis elegans plasmid construction. The human tau::EGFP
fusion plasmid for expression in C. elegans was constructed using Gate-
way technology (Invitrogen, San Diego). Specifically, the unc-54 pro-
moter plasmid pPD30.38 (a gift from A. Fire, Delft University of Tech-
nology, Delft, The Netherlands) was converted into a Gateway
destination vector, pDEST-UNC-54, using Gateway technology. Addi-
tionally, a Gateway entry vector for tau::EGFP was generated by BP reac-
tion with pDONR221 using PCR-amplified cDNA fragments from vec-
tor GFP-4R0N-WT tau. After this, the tau::EGFP fusion was cloned into
the pDEST-UNC-54 vector via an LR reaction.
C. elegans vector delivery, imaging, and quantitation. The plasmid
encoding the wild-type human tau::EGFP fusion was injected into the
gonads of early-adult hermaphrodites (strain N2, Bristol) at a con-
centration of 0.1 g/ml. The injection mixture contained vector
Punc-54::tau::EGFP as well as pRF4 rol-6 (su1006 ) as a dominant marker
for transformation selection [as was green fluorescent protein (GFP)
fluorescence] (Mello et al., 1991). Multiple worm lines expressing stable
extrachromosomal arrays were obtained. After stable transmission of the
arrays, multiple stable lines were compared and analyzed before a con-
sensus line was integrated into the genome. Integration was performed
using gamma irradiation with 3500 – 4000 rads from a Cobalt 60 source
(Inoue and Thomas, 2000). The integrated transgenic lines were named
according to appropriate C. elegans nomenclature as strains UA38
(baIn38) and UA39 (baIn39).
C. elegans strains UA38 and UA39 were cultured under standard con-
ditions (Brenner, 1974). RNA interference (RNAi) was used to disrupt
the expression of chn-1, the C. elegans ortholog of CHIP, using the bac-
terial feeding method (Timmons et al., 2001). The chn-1-containing frag-
ment cloned into L4440 was obtained from the genomic library of RNAi
targeting bacterial strains from the MRC GeneService (Kamath and Ahr-
inger, 2003). Controls for RNAi specificity were determined on basis of
unique Wormbase-predicted targets. Transformed HT115 (DE3) bacte-
ria were grown for 14 h at 37°C in Luria broth supplemented with 50
g/ml ampicillin. These cultures were plated onto standard [nematode
growth medium (NGM)] worm plates containing 1 mM isopropyl -D-
1-thiogalactopyranoside to induce double-stranded RNA (dsRNA) pro-
duction and were allowed to grow overnight at room temperature.
Transgenic worms at the L4 stage were then placed onto these RNAi
plates. The F1 generation offspring were subsequently transferred to
fresh chn-1 RNAi plates, and their progeny (F2 generation) were exam-
ined as young adults for evidence of tau::EGFP expression. Worms were
examined with a Nikon (Tokyo, Japan) E800 epifluorescence microscope
using an Endow GFP HYQ filter cube. Images were captured with a Cool
Snap HQ CCD camera (Photometrics, Tucson, AZ) driven by Meta-
Morph software (Universal Imaging Corporation, West Chester, PA).
Preparation of C. elegans extracts for immunoblotting. Extracts were
prepared after growth of strain UA38 to near confluence on two 100 mm
NGM plates with and without bacteria expressing dsRNA targeting
chn-1. Worms were collected by washing with M9 buffer and concen-
trated by centrifugation in a 1.5 ml microcentrifuge tube at 5000  g for
1 min. The worm pellet was resuspended and lysed in buffer containing
50 mM Tris, 274 mM NaCl, 5 mM KCl, 2% SDS, and a protease and
phosphatase inhibitor mixture, pH 8.0. After homogenization and soni-
cation, 20 g of protein (as determined by BCA assay) were loaded with
equivalent volumes of SDS-PAGE sample buffer and subjected to SDS-
PAGE Western blot analysis.
Breeding of CHIP/, CHIP/  Tau P301L, and twitcher mice colo-
nies and tissue harvesting. Mice lacking CHIP expression (CHIP /)
were generated as described previously (Dai et al., 2003). Briefly, a neo-
cassette was inserted into the CHIP gene, replacing exons 1–3. Mice were
maintained on a mixed SvEv129/C57BL6 background and housed in a
barrier facility. Heterozygote or homozygote mice lacking one or both
alleles, respectively, were genotyped by PCR from tail-clip digestions
(Dai et al., 2003). Tau P301L mice were as described previously (Lewis et
al., 2000). CHIP / mice were bred with JNPL3 on a Swiss Webster
background to generate CHIP /  JNPL3 mice. These mice were back-
crossed to CHIP / mice to generate CHIP /  Tau P301L (CHT)
mice. Breeding pairs of twitcher heterozygotes and C57BL/6J mice were
purchased from The Jackson Laboratory (Bar Harbor, ME). The geno-
types of pups born from the twitcher heterozygotes were determined by
PCR (Sakai et al., 1996). CHIP /, CHIP /, JNPL3, CHT, and
twitcher mice were humanely killed at postnatal day 25 (P25) to P30, and
brains were quickly removed for dissection. The left cerebral hemisphere
was immediately fixed in 10% formalin, and the other half was frozen on
dry ice for subsequent biochemical and RNA analyses.
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Quantitative real-time PCR. RNA was isolated from tissue samples and
analyzed by quantitative real-time PCR (qRT-PCR) as described previ-
ously (Dickey et al., 2003). Briefly, total RNA samples from the ventral
half of four CHIP / and four CHIP / mice right brain hemispheres
were isolated using RNeasy technology from Qiagen (Valencia, CA) and
reverse transcribed with Moloney murine leukemia virus reverse tran-
scriptase and 1 M betaine. RNA was isolated after growth of strain UA38
to near confluence on 12 100 mM NGM plates with chn-1 siRNA bacteria
or siRNA bacteria only. Worms were collected by washing with M9 buffer
and concentrated by centrifugation in a 1.5 ml microcentrifuge tube at
1600  g for 1 min. Worms were washed in M9 three times. Worm lysis
was achieved via vortexing Trizol-treated worms with 150 –212 m glass
beads. A standard curve was established within the reverse transcription
reaction by adding total RNA (template) from an intra-experimental
mouse RNA pool covering 3 logs. Five nanograms of total RNA from all
samples were added to individual wells within the reverse transcription
reaction for comparison to the standard curve. Primers for SYBR Green
analysis by PCR were generated to as described previously (Dickey et al.,
2004). To ensure that DNA contamination would not contribute to the
detected signal, primers for CHIP were designed to span intron 1 (for-
ward, 5-CCAGCTGGAGATGGAGAGTT-3; reverse, 5-GCCGTTC-
CTCGATACTGTTC-3). The primers for C. elegans were chn-1 forward
5-CACTGGAACTGAGCCCAAAC-3 and reverse 5-GAGCGTTC-
GTGATAACAGCA-3. Experimental wells containing 12 l PCRs were
run in quadruplicate in 384-well plates. PCR was run on the ABI 7900 as
follows: 1 cycle of 95°C for 15 min, followed by 40 cycles of 95°C for 15 s
and 60 – 65°C for 1 min. None of the primer pairs demonstrated more
than one peak of fluorescence from melt-curve analysis. The standard
curve was calculated by plotting the threshold cycle (Ct) against the log
nanogram quantity of RNA added to the RT reactions. A linear regres-
sion was performed, and the slope, relating Ct to log nanogram RNA, was
calculated and converted to a mass quantity of standard RNA. These
mass values for the genes of interest were then normalized to 28S ribo-
somal RNA mass values and divided by GAPDH mRNA to determine
fold change in expression relative to the standard RNA pool. For C.
elegans, values were normalized to the GAPDH ortholog gpd3. These fold
change values for samples in the CHIP / and CHIP / groups were
analyzed for significance using Student’s t test.
Sarkosyl-soluble and insoluble tissue preparation. After brain tissue was
harvested as described above, each sample was homogenized in buffer
containing 50 mM Tris, 274 mM NaCl, 5 mM KCl, 100 mM PMSF, and a
protease and phosphatase inhibitor mixture, pH 8.0. Homogenates were
centrifuged at 60,000 rpm for 15 min, and supernatant was saved as a
“soluble” (S1) fraction. The remaining pellet was homogenized in buffer
containing 10 mM Tris HCl, 0.8 M NaCl, 10% sucrose, 1 mM EGTA, and 1
mM PMSF, pH 7.4, and recentrifuged at 60,000 rpm for 15 min. The
supernatant from this spin was incubated with 1% Sarkosyl at 37°C for
1 h. This mixture was then centrifuged at 60,000 rpm for 30 min, and the
supernatant was removed as the “Sarkosyl-soluble” (S2) fraction. The
remaining pellet was suspended in Tris–EDTA buffer and kept as
the “Sarkosyl-insoluble” (P3) fraction.
Western blotting. Cell lysates were sonicated, and tissue samples were
homogenized and processed as described above. Protein concentrations
were measured by a standard BCA assay (Pierce, Rockford, IL). Cell lysate
samples and fractionated tissue homogenates were then heated in
Laemmli’s buffer, and equal amounts of protein were loaded into 10- or
15-well 10% Tris-glycine gels (Novex, San Diego, CA). After transfer,
blots were blocked with Blotto (5% nonfat dry milk in TBS plus 0.1%
Triton X-100) for 2 h, and antibodies were applied at appropriate dilu-
tions in Blotto overnight at 4°C. Membranes were washed three times for
10 min in TBS with 0.05% TBS plus 0.1% Triton X-100 and incubated
with secondary antibody for 1 h. Membranes were then washed three
times for 10 min, and protein expression was visualized by ECL treat-
ment and exposure to film. Bands were quantified using Scion (Freder-
ick, MD) Image by analyzing pixel density. A semiquantitative analysis
was performed by densitometry, correcting protein levels for GAPDH.
For studies using the Odyssey scanner (Li-Cor, Lincoln, NE), conditions
were similar to those described above; however, Li-Cor Odyssey blocking
buffer was used in place of Blotto, and fluorescent-labeled [AlexaFluor
680 and Rockland (Gilbertsville, PA) IRDye800CW] secondary antibod-
ies were used for detection.
Coimmunoprecipitation with PHF1 tau and Tau5 monoclonal antibod-
ies. Coimmunoprecipitation (co-IP) to assess tau ubiquitination levels in
CHIP /, CHT, and JNPL3 mice was performed as described previously
(Petrucelli et al., 2004). Briefly, 750 g of total protein from CHIP /,
CHIP /, CHT, and 4R0N P301L tau transgenic mouse tissue homog-
enates were suspended in 250 l of co-IP buffer, sonicated, and incu-
bated with 20 l of protein G to pre-clear lysates for 1 h. After centrifu-
gation, supernatants were incubated with anti-tau Tau5 antibody, anti-
pS396/S404 tau PHF1 antibody, and 50 l of protein G overnight at 4°C.
Supernatants were washed three times in co-IP buffer, resuspended in
sample buffer, and subjected to Western blot analyses after SDS-PAGE
without controlling for protein concentration. Blots were probed with
ubiquitin and total tau antibodies.
Alkaline phosphatase assay. Tissue was homogenized in buffer contain-
ing 50 mM Tris-HCl, pH 7.4, 1 M NaCl, 0.1% Triton-X, 5 mM EDTA plus
1% SDS, PMSF, and a protease inhibitor mixture. One hundred micro-
grams of protein were suspended in 100 l of 50 mM Tris HCl and 1 mM
MgCl2 buffer and incubated at 30°C for 10 min. 30 U of calf intestine
alkaline phosphatase were added to the samples and incubated at 30°C
for 15 min. An equal volume of SDS-PAGE sample buffer was added to
stop reactions, and samples were subjected to SDS-PAGE.
Immunohistochemistry. Immunohistochemistry was performed on
paraffin-embedded 5-m-thick sections mounted on glass slides. The
sections were deparaffinized and rehydrated in xylene and a graded series
of alcohol and subjected to antigen retrieval with steaming in distilled
H2O for 30 min. The tissue sections, along with positive and negative
controls, were processed in a batch to assure uniformity, in a Dako Au-
tostainer. The detection system used was the EnVision HRP system
(Dako), and antibodies were diluted in Dako Antibody Diluent with
background reducing components. The Liquid DAB Substrate-
Chromogen system (Dako) was used as the chromogen. The stained
slides were lightly counterstained in hematoxylin, dehydrated, and cov-
erslipped. Terminal deoxnucleotidyl transferase-mediated dUTP nick
end labeling (TUNEL) was performed using the Apoptag peroxidase kit
(Chemicon, Temecula, CA) according to the manufacturer’s instruc-
tions, as described previously (Zehr et al., 2004). The chromogen 3,3-
diaminobenzidine was used to visualize staining. Sections were counter-
stained with methyl green.
Electron microscopy. For routine ultrastructural studies, brains were
removed and fixed overnight at 4°C in 2.5% glutaraldehyde in 0.1 M
cacodylate buffer, pH 7.4. After washing in cacodylate buffer, the tissues
were postfixed in 1% OsO4, en bloc stained in 1% uranyl acetate–50%
ethanol, dehydrated in ethanols and propylene oxide, infiltrated, and
embedded in Epon 812 (Polysciences, Warrington, PA). Ultrathin sec-
tions were counterstained with uranyl acetate and lead citrate and exam-
ined with a Philips 208S electron microscope.
Immunoelectron microscopy. For postembedding immunoelectron mi-
croscopy, 4% paraformaldehyde-fixed brain tissue was dehydrated in
graded ethanol, infiltrated in LR White resin (Polysciences, Warrington,
PA), and polymerized in a vacuum oven at 50°C for 2 d. Ultrathin sec-
tions were collected on Formvar-coated nickel grids and used for immu-
nocytochemistry as reported previously (Lin et al., 2003). The antibodies
used from immunoelectron microscopy were CP13 (mouse monoclonal
antibody to phosphorylated tau, pS202/T205, neat; from Dr. P. Davies)
(Weaver et al., 2000) and E1 (polyclonal antibody to human tau; dilu-
tion, 1:200) (Crowe et al., 1991).
Results
CHIP / mice have reduced neuronal HSP70 RNA and
protein levels and accumulate phospho-tau protein without
affecting its transcription or other synaptic proteins
We demonstrated recently that CHIP and HSP70 were critical for
the removal of tau and that CHIP-mediated ubiquitination of tau
lead to increased accumulation of tau in an insoluble fraction
(Petrucelli and Dawson, 2004). HSP70 overexpression had op-
posing effects. To better understand the role of CHIP in tau pro-
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cessing, we used mice deficient in CHIP
expression to determine whether it is indeed
essential for removal of phosphorylated tau
species or involved in tau aggregation
through its effects on ubiquitination.
Founders used for previously described
work by Dai et al. (2003) were used to gener-
ate a CHIP/ in-house breeding colony.
We found that 25% of the mice from our
colony died at P30–P35, and these animals
were distinctly smaller and feebler than their
littermates (Fig. 1A), developing motor def-
icits around P20. Genotype analysis showed
that these animals were indeed CHIP/
mice; however, there were additional mice
(25%) that were identified as CHIP deficient
by PCR but lacked the small phenotype and
possessed similar survival traits to wild-type
siblings. Therefore, we decided to analyze
tau levels in the small, symptomatic (sx)
CHIP/ mice and age-matched asymp-
tomatic (asx) CHIP/ mice, treating them
as separate cohorts. Postmortem biochemical analyses of these mice
with an antibody against total tau revealed a substantial increase in
tau burden in sx CHIP/ mice, particularly higher molecular
weight tau species (subsequently shown to be phospho-tau), that
was not present in age-matched CHIP/, CHIP/, or the re-
maining asx CHIP/ littermates, nor was there any indication after
4.5 months of age that tau was accumulating (Fig. 1B). Further aging
of these mice to 8 months did not precipitate aberrant tau accumu-
lation (data not shown). This disparity in the CHIP/ mice was
most likely attributable to the use of non-isogenic founders to estab-
lish our line (Suzuki and Nakayama, 2003), bringing about allelic
differences that resulted in the split phenotype. Therefore, given the
unique and robust accumulation of tau demonstrated by the sx
CHIP/ mice, we focused our efforts on characterizing the neuro-
pathology of these animals. For simplicity, sx CHIP/ will be re-
ferred to as CHIP/ mice unless noted otherwise.
Using qRT-PCR, we validated that CHIP mRNA expression
was indeed absent in these mice and determined that neither tau
nor microtubule-associated protein 2 (MAP2) mRNA expression
was changed compared with wild-type littermates (Fig. 2A). We
also demonstrated that HSP70 mRNA expression was decreased,
confirming that heat shock factor-1 (HSF1) activity was de-
creased because of CHIP deficiency in brain tissue, similar to
previous findings in the periphery by Dai et al. (2003) (Fig. 2A).
Interestingly, HSP27 mRNA levels were unaltered in these mice
(data not shown), suggesting that the primary transcriptional
machinery for this gene may not be HSF1. Western blot analyses
demonstrated that CHIP protein was undetectable and HSP70
levels were decreased in CHIP/ mice, consistent with the re-
ductions in mRNA expression (Fig. 2B). Using a larger cohort of
these mice, we confirmed that phospho-tau and total tau levels
were dramatically increased. Given that tau mRNA levels were
unchanged, this result was consistent with the role of CHIP in
posttranslational tau protein degradation (Petrucelli et al., 2004;
Shimura et al., 2004). To better establish the specificity of CHIP
for tau, MAP2 protein levels were assessed and found to be un-
changed (Fig. 2B). Immunohistochemical analyses comparing
CHIP/ and CHIP/ mice showed S202/T205 phospho-tau
immunoreactivity in neuropil of forebrain and hindbrain gray
matter in CHIP/ mice that was not detected in age-matched
CHIP/ mice (Fig. 2C).
CHIP / mice develop marked accumulation of soluble,
ubiquitin-negative, phosphorylated tau species
Additional biochemical analyses of the CHIP/ mice revealed a
marked elevation in multiple phospho-tau species within the
Sarkosyl-soluble protein fraction compared with age-matched
CHIP/ littermates, including positive immunoreactivity with
antibodies generated against the pS396/S404 ( p  0.0003),
pS202/T205 ( p  0.014), and pS262/S356 ( p  0.031) epitopes
on human tau (Fig. 3A). No abnormal accumulation of 60 –72
kDa tau was seen in the Sarkosyl-insoluble protein fraction (data
not shown). Treatment of homogenates with alkaline phospha-
tase (PPase) produced a collapse of the predominant 60 kDa
molecular weight tau species in the CHIP/ tissue into lower
molecular weight species near the molecular weight of nonphos-
phorylated tau (55 kDa; detected with the Tau5 total tau anti-
body) (Fig. 3C), and immunoreactivity for pS396/S404 tau was
mostly eliminated. Nonphosphorylated tau at S199/S202, recog-
nized by the Tau 1 antibody, was significantly decreased ( p 
0.0008) in the CHIP/ homogenate compared with CHIP/
littermates (Fig. 3A). Other proteins that were probed for, includ-
ing -synuclein and MAP2 (Fig. 3A), along with three other pu-
tative CHIP substrates (androgen receptor, Smad3, and nNOS)
based on previous in vitro studies remained unchanged in the
CHIP/ mice (data not shown). Although total tau levels were
elevated significantly ( p  0.035) as measured by chemilumines-
cent Western analysis, we endeavored to definitively establish
that tau was accumulating because of impaired degradation re-
sulting from CHIP deletion, rather than simply enhanced kinase
or decreased phosphatase activities. Thus, using a fluorescent-
based Western blot approach for a more quantitative assessment
of tau levels, we were able to further validate that the levels of total
tau protein in the CHIP/ mice were twice that in wild-type
littermates ( p  0.0012) (Fig. 3B).
We then performed a coimmunoprecipitation experiment
on brain homogenates from CHIP /, CHIP /, and JNPL3
mutant P301L tau mice [as a phospho-tau positive control
(Lewis et al., 2000; Sahara et al., 2005)]. Although accumula-
tion of ubiquitinated tau at 1 month of age in mice is normally
very low, there were slight indications that more ubiquitin-
positive tau was present in the CHIP / mice compared with
CHIP / mice; however, more striking was the absence of
Figure 1. A large subset of CHIP / mice demonstrates P30 –P35 morbidity and marked accumulation of cerebral phospho-
tau levels. A, Symptomatic CHIP / mice are substantially smaller than either age-matched asymptomatic CHIP / or wild-
type littermates. B, Whole brain was extracted from 30-d-old symptomatic CHIP / mice and 30-d-old and 4.5-month-old
asymptomatic CHIP / mice, with age-matched wild-type littermates (n  2), and homogenized for SDS-PAGE. Western blot
analysis was performed using near-infrared fluorescent detection for total tau and GAPDH levels (in kilodaltons). No difference in
total tau levels was observed in the asymptomatic CHIP / mice at either age compared with wild-type controls. SX, Symptom-
atic; ASX, asymptomatic; mo., month.
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polyubiquitinated tau in CHIP / mice in contrast to the
large amount of polyubiquitinated tau in JNPL3 mice (Fig.
3D) despite both models having substantial phospho-tau
burden (Lewis et al., 2000). Therefore, only the JNPL3 mice
demonstrated polyubiquitination of phospho-tau species,
presumably mediated by endogenous CHIP activity that is
absent in CHIP / mice.
Presynaptic and perikaryal accumulation of phospho-tau
but not Alzheimer type tau conformational epitopes in
CHIP / mice
Immunohistochemical studies of CHIP/ mice (Fig. 4) showed
increase in phospho-tau recognized by the pS202/T205 anti-
body (CP13) in the cerebral cortex, hippocampus, olfactory
bulb, midbrain tectum, and cerebellar deep nuclei (Fig. 4 A–
D). Immunoreactivity was more robust for pS202/T205 (Fig.
4 E, F, CP13) than pS396/S404 (Fig. 4G,H, PHF-1), as demon-
strated in hippocampal mossy fibers and the cerebellar molec-
ular layer. Mossy fibers were less intensely immunoreactive for
pS262/S356 tau (Fig. 4 I) and normal tau with Tau5 (Fig. 4 K),
whereas both antibodies showed Purkinje cell perikaryal stain-
ing (12E8 more than Tau5) rather than molecular layer neu-
ropil. The paucity of immunoreactivity for total normal tau is
not unexpected because it is difficult to detect normal tau in
tissue that has not been perfused, presumably as a result of
rapid breakdown of microtubules during brain removal and
fixation. The ability to detect any normal tau immunoreactiv-
ity is remarkable and fits with the increased expression de-
tected in biochemical analyses (Fig. 3A). There was no evi-
dence of either perikaryal or neuropil immunoreactivity with
MC1, a monoclonal antibody that recognizes conformational
changes in tau seen in neurofibrillary degeneration (Weaver et
al., 2000) (Fig. 4 M, N ). The phospho-tau immunoreactivity of
CHIP / mouse brain was suggestive of presynaptic distribu-
tion, and localization in mossy fibers in the hippocampus and
cerebellum is consistent with this observation, which was later
confirmed by immunoelectron microscopy studies (see Fig. 10).
Stress state alone does not precipitate
phospho-tau accumulation
To validate that this marked accumulation of phospho-tau
was indeed attributable to the absence of CHIP and not simply
a result of aberrant kinase activation or stress-associated ac-
tivities of the sx CHIP / mice, we examined levels of tau in
another diseased mouse model that has a very similar pheno-
type caused by a naturally occurring nonsense mutation in the
GALC (galactosylceramidase) gene (Duchen et al., 1980). The
twitcher mice can be identified phenotypically by their failure
to thrive and hindlimb paralysis (Kobayashi et al., 1980),
which coincides quite similarly with the phenotypic progres-
sion of the sx CHIP / mice. Therefore, these mice provided
an appropriate disease control model to test whether agonal
state alone can facilitate tau accumulation. Both total tau and
phospho-tau levels were assessed in P30 sx CHIP / and
twitcher mice by Western blot, and as demonstrated in previ-
ous figures, CHIP null mice have a marked accumulation of
phospho-tau species in the soluble fraction; however, twitcher
mice showed no evidence of tau accumulation despite their
moribund condition (Fig. 5). Therefore, these results power-
fully demonstrate that it is the absence of CHIP activity pro-
moting the degradation of phospho-tau species that is provok-
ing its abnormal accumulation, not the overall debilitated
condition of these mice.
RNAi for CHIP and the C. elegans ortholog chn-1 promotes
accumulation of abnormally phosphorylated tau in both a
mouse neuroblastoma cell line and a transgenic nematode line
To further investigate the impact of CHIP on the degradation of
tau protein, isogenic strains of transgenic C. elegans expressing a
protein fusion between wild-type human tau and enhanced GFP
(EGFP) in the bodywall muscles were generated to facilitate di-
Figure 2. CHIP / mice have reduced neuronal HSP70 RNA and protein levels and accu-
mulate phospho-tau protein without affecting its transcription or other microtubule-associated
proteins. Total RNA from 30-d-old CHIP / mice (n  4) and non-transgenic littermate (n 
4) brain tissue was extracted, and expression was analyzed by real-time PCR. Tau and MAP2
mRNA levels were unchanged in CHIP / mice relative to non-transgenic littermates after
normalizing for GAPDH. A, CHIP was confirmed to be absent, and HSP70 levels were reduced,
consistent with the previously described relationship between CHIP and HSF1 activity (**p 
0.01). KO, Knock-out; W/T, wild type. Error bars represent  SD. B, Brain protein levels (in
kilodaltons) were assessed by Western blot analysis, confirming the absence of CHIP and reduc-
tions in HSP70 protein levels in CHIP / mice; however, pS202/T205 (CP13) tau levels were
only observed in CHIP / mice. Elevations in total tau were also demonstrated. MAP2 and
GAPDH levels remained unchanged, suggesting selectivity of CHIP for phospho-tau degrada-
tion. C, Levels of pS202/T205 (CP13) tau were also assessed by immunohistological methods,
which revealed increases in phospho-tau species throughout the neuropil of forebrain and
hindbrain gray matter in CHIP / mice compared with 30-d-old age-matched littermates as
illustrated in the olfactory bulb.
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rect comparison of the effect of CHIP gene
knockdown on tau protein levels by RNAi.
The C. elegans ortholog of CHIP, chn-1
[see sequence alignment using the Clustal
program (Chenna et al., 2003)] (supple-
mental Fig. 1, available at www.jneuro-
sci.org as supplemental material), is ubiq-
uitously expressed in many tissues
including the muscles of the bodywall. As
depicted in Figure 6, worms fed bacteria
producing dsRNA targeting the C. elegans
chn-1 exhibited a dramatic increase in
tau::EGFP fluorescence in the bodywall
muscles (C, D) compared with control an-
imals fed RNAi bacteria only (A, B). Spe-
cifically, in the case of isogenic strain
UA38, tau::EGFP worms exposed to chn-1
dsRNA displayed robust fluorescence
throughout the bodywall muscle tissue in
96.4% of animals tested. This is in contrast
to the 9.9% of transgenic worms observed
with high levels of tau::EGFP fluorescence
in the absence of chn1 RNAi treatment
( p  0.003). A similar significant increase
in tau levels was observed using a separate
transgenic line (UA39; p  0.001). West-
ern blot analyses of the soluble (S1) frac-
tions from these worms demonstrated
that tau levels in transgenic worms ex-
posed to chn-1 RNAi realized dramatic
increases in both total and phosphory-
lated GFP-tagged tau protein levels (Fig.
6 E). Worms grown on the RNAi bacte-
rial control strain did not exhibit an in-
crease in tau::EGFP levels over unin-
duced chn-1 RNAi animals (Fig. 6 E).
Real-time PCR analysis of chn1 mRNA
levels demonstrated 50% reductions
in worms fed chn1 RNAi bacteria com-
pared with those fed RNAi bacteria alone
(Fig. 6 F). We then went on to generate
siRNA to specifically knockdown CHIP
expression in a mouse neuroblastoma
cell line (N2A). When CHIP protein was
effectively absent because of CHIP
RNAi, phospho-tau recognized by a
pS396/S404-specific antibody was sig-
nificantly increased by 40 – 45%, and to-
tal tau levels were increased by 20 –25%
compared with cells exposed to an
siRNA control (n  4) (Fig. 6G,H ). Sta-
tistical analysis comparing the increases
in phospho-tau compared with total tau
levels demonstrated that phospho-tau was preferentially accu-
mulating compared with overall tau levels (20% greater in-
crease) (Fig. 6 I).
Caspase-3 activation is increased in CHIP / mice and is
associated with increased apoptosis and elevated levels of
caspase-3-cleavage of tau
Although it has been demonstrated previously that caspase-3 ac-
tivity is increased in peripheral tissues in CHIP/ mice (Dai et
al., 2003), it remained to be determined (1) whether this apopto-
tic marker was a developmental consequence of CHIP deletion,
(2) whether it was similarly elevated in terminally differentiated
neurons, and (3) whether there was a functional link with tau. To
address the first issue, RNAi was used to knockdown CHIP RNA
expression in N2A cells. RNAi of CHIP caused increases not only
in total caspase-3 levels but also in the cleavage product of
caspase-3 (cleaved caspase-3) compared with cells treated with a
scrambled siRNA, indicating apoptotic activation (Fig. 7A). Tau
cleaved by caspase-3 was also slightly elevated in these cells. This
in vitro result demonstrated that caspase activation occurring in
Figure 3. CHIP / mice develop marked accumulation of soluble phosphorylated tau species. A, Whole brain was extracted
from 30-d-old CHIP / mice (n  4; gray bars) and non-transgenic littermates (n  4; black bars) and homogenized for
SDS-PAGE and Western blot analyses (left), and bands were quantitated by densitometry (right). Probing for three distinct
phospho-tau epitopes at S396/S404 (PHF1), S202/T205 (CP13), and S262/S356 (12E8) demonstrated a marked elevation in these
tau species in CHIP / mice. Total tau levels were also elevated with a distinct upward shift in the molecular weight of nearly
50% of the total protein levels. Tau dephosphorylated at S199/S202 (detected by the Tau 1 antibody) was decreased in CHIP /
mice, indicating a conversion of total tau to a phosphorylated state. Synuclein levels, which are also affected by ubiquitination,
remained unaffected because of CHIP deletion, thus further suggesting selectivity of CHIP for tau. No differences were detected in
MAP2 or GAPDH levels. **p  0.01; ***p  0.001. B, Western blot analysis of the same mice in A using near-infrared fluorescent
detection for tau and GAPDH levels. **p  0.01. Error bars represent  SD. C, Homogenates were also subjected to alkaline
phosphatase (Alk. PPase) treatment, and tau levels were assessed by Western blot to determine which species of total tau were
phosphorylated. To confirm dephosphorylation efficiency by alkaline phosphatase, we first probed with the pS396/S404 tau
antibody (PHF1) and demonstrated that nearly all tau becomes dephosphorylated after treatment. Subsequent probing for total
levels showed that the upper molecular weight species seen in the CHIP / brain homogenate are primarily hyperphosphory-
lated forms of tau. D, Coimmunoprecipitation (IP) for total tau and subsequent probing for ubiquitin and total tau demonstrated
that 4-week-old CHIP / mice, which have a substantial phospho-tau burden comparable with, if not greater than, 34-week-
old transgenic mice overexpressing mutant human tau, are unable to ubiquitinate tau species. Even CHIP / mice that lack any
type of tau pathology have slightly increased levels of ubiquitinated tau compared with CHIP / mice, further suggesting that
endogenous mouse tau is indeed a target of CHIP activity. For blots, values shown on the right are in kilodaltons.
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the CHIP/ mice was likely not attributable to a developmental
compensation but rather was a direct result of the loss of CHIP
activity. Western blots for both caspase-3 and cleaved caspase-3
in CHIP/ brain homogenate also revealed elevated caspase-3
expression and activity in these mice compared with CHIP/
littermates (Fig. 7B), and qRT-PCR demonstrated a 70% increase
in caspase-3 mRNA levels, thus answering the second question as
to whether caspase-3 was elevated in the CNS. Finally, to address
the third issue regarding caspase-3 activity in CHIP/ mice, we
used an antibody that selectively detects tau after it has been
cleaved by caspase-3 (Tau-C3) to demonstrate that caspase-3-
mediated tau cleavage was significantly in-
creased in CHIP/ mice compared with
CHIP/ littermates (Fig. 7B). Immuno-
histochemical analyses further demon-
strated weak Tau-C3 immunoreactivity in
the neuropil but not aggregated in
perikarya of CHIP/ mice (Fig. 7C). Im-
munostaining for cleaved caspase-3 dem-
onstrated abundant apoptotic bodies in
regions with high levels of phospho-tau
immunoreactivity particularly within the
deep cerebellar nuclei (Fig. 7D), cerebellar
internal granular layer, olfactory bulb,
midbrain tectum, and basal layers of the
hippocampal dentate fascia. Apoptotic ac-
tivation was also assessed by TUNEL.
TUNEL-positive cells were detected
throughout the brain, but particularly in
regions that also showed high phospho-
tau levels, including the midbrain tectum
(Fig. 7E). The cytologic profile of both
cleaved caspase-3 and TUNEL-labeled
cells was consistent with apoptosis, with
nuclear condensation and fragmentation.
Not all apoptotic bodies detected with nu-
clear counterstains (hematoxylin or
methyl green) were labeled by both meth-
ods. In age-matched CHIP/ littermates,
apoptotic bodies were limited to sparse
cells in the olfactory bulb, subventricular
zone, and basal layers of the hippocampal dentate fascia (data not
shown).
CHIP-deficient mice overexpressing a mutant form of human
tau convert all human tau into a higher molecular weight
species but still fail to accumulate insoluble tau species or
develop pre-tangle-like structures compared with littermates
To determine the effect that mutant human tau may have on the
phenotype and pathology of CHIP/ mice, we bred the JNPL3
mutant tau strain with CHIP/ mice to generate CHT mice.
Although Western blot analyses of the CHT mice revealed that
phospho-tau levels (pS396/S404) were identically elevated be-
tween CHIP/ and CHT mice compared with JNPL3 and
CHIP/ littermates, there was an upward shift in the molecular
weight of human tau-immunoreactive species by 5 kDa in CHT
mice compared with JNPL3 littermates (Fig. 8A). These species
collapsed to normal tau molecular weight species after phospha-
tase treatment (as described above). Immunoprecipitation of tau
from both CHT and age-matched JNPL3 littermates confirmed
that the tau accumulating in these mice was not polyubiquiti-
nated, whereas the tau present in age-matched JNPL3 mice was
(Fig. 8B).
Immunohistochemical analyses for human tau immunoreac-
tivity using the E1 antibody comparing CHT mice with age-
matched JNPL3 littermates revealed that JNPL3 mice had
marked perikaryal staining (“pre-tangles”) in the CA3 and CA1
pyramidal neurons of the hippocampus, as well as neurons in the
brainstem, whereas CHT mice had mostly neuropil (Fig. 9D) or
neuritic (axonal/presynaptic) staining, for example in mossy fi-
bers in CA3 (Fig. 9B) or in brainstem (Fig. 9F).
Additional immunohistochemical analysis in CHT mice con-
firmed the presence of diffuse neuropil phospho-tau (S202/
T205) immunoreactivity in the presynaptic neuronal compart-
Figure 4. Presynaptic and perikaryal accumulation of phospho-tau but not Alzheimer-type tau conformational epitopes in
CHIP / mice. A, Neocortical sections show diffuse neuropil immunoreactivity with CP13 (pS202/T205) revealing a negative
outline of apical dendrites of pyramidal neurons. B–D, CP13 immunoreactivity was present in occasional neuronal perikarya in the
olfactory bulb (B), midbrain tectum (C), and cerebellar deep nuclei (D), regions that also had increased neuronal apoptosis (see
Fig. 7 D, E). E, G, I, K, M, Adjacent sections of the hippocampal CA3 sector of a CHIP / mouse show phospho-tau immunoreac-
tivity of mossy fibers with CP13 (pS202/T205; E), PHF1 (pS396/S404; G), 12E8 (pS262/S356; I ), and tau 5 (total normal tau; K ) but
not MC1 (Alzheimer-type conformational tau epitope; M ). F, H, In the cerebellar molecular layer, there is diffuse neuropil staining
of the molecular layer, consistent with a presynaptic distribution with antibodies to phospho-tau, CP13 (F ), and PHF1 (H ). J, L, N,
There is more perikaryal staining with 12E8 (J ) and tau 5 (L) but neither neuropil nor perikaryal immunoreactivity with MC1 (N ).
Figure 5. Stress state alone does not precipitate phospho-tau accumulation. Whole brain
was extracted from 30-d-old CHIP / mice, twitcher (Galc /) mice, and age-matched wild-
type littermates (n  2) and homogenized for SDS-PAGE and Western blot analysis. Membrane
was probed for total tau, CP13 (pS202/T205), CHIP, and GAPDH levels (in kilodaltons). Tau
accumulation was present only in the CHIP / mice compared with the twitcher mice or
wild-type controls.
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ment (Fig. 10A) that showed no staining
with the Gallyas silver stain (Fig. 10B). Im-
munostaining for E1 revealed neuritic
staining in cerebellar internal granular cell
layer within glomeruli (Fig. 10C). Electron
microscopy was used to investigate the na-
ture of the cerebellar glomerular immuno-
reactivity, which had the morphology of
presynaptic mossy fiber terminals. In tis-
sue fixed in the absence of glutaraldehyde
for immunoelectron microscopy (Fig.
10E,F) immunogold was concentrated in
the glomeruli in structures that were rich
in synaptic densities and mitochondria
consistent with mossy fiber termini. In tis-
sue that had been fixed with glutaralde-
hyde to preserve ultrastructural morphol-
ogy (Fig. 10D), there was no evidence of
tau filaments in mossy fiber termini (Fig.
10D).
Discussion
Recent progress toward understanding the
involvement of the UPS in disorders asso-
ciated with protein aggregation has impli-
cated a subset of chaperones in removal of
abnormal proteins in a number of neuro-
degenerative diseases (Korhonen and
Lindholm, 2004). Several recent studies
have implicated the unique U-box ubiq-
uitin ligase CHIP as a necessary compo-
nent for the sequestration and removal of
aberrant proteins prone to aggregation in
neurological disorders (Sahara et al., 2002;
Urushitani et al., 2004; Miller et al., 2005). Despite these findings,
a definitive link between ubiquitination of tau and its aggregation
has yet to be established; however, several lines of correlative
evidence do exist. Recently, our group implicated CHIP as the
primary ubiquitin ligase for tau, and, as such, tau lesions in AD
consistently stain positive for CHIP (Petrucelli et al., 2004).
Moreover, levels of CHIP were found to be elevated in AD, fur-
ther suggesting the role of CHIP in tangle maturation (Sahara et
al., 2005). Immunoelectron microscopy of filaments isolated
from AD and other tauopathies shows direct incorporation of
ubiquitin in tau filaments (Yang and Ksiezak-Reding, 1998),
whereas immunohistochemical studies of AD conducted over a
decade ago suggested that ubiquitination may be associated with
a relatively late stage of NFT formation, preceding accumulation
of phospho-tau species (Bancher et al., 1991). Indeed, the study
by Sahara et al. (2005), in which an 18-month-old CHIP/
mouse was analyzed, demonstrated that there was a slight in-
crease in SDS-insoluble tau in this animal compared with an
age-matched littermate. The current study challenges the notion
that polyubiquitination of tau occurs only after NFT formation
has initiated. We suggest that ubiquitination of excess phospho-
tau facilitates tau aggregation and/or Sarkosyl insolubility as an
adaptive neuronal response when the degradative machinery is
overwhelmed, as in a diseased state or in models of
overexpression.
Previously, our group and others demonstrated that CHIP
specifically bound to tau within the microtubule binding region,
and other reports revealed that tau is indeed polyubiquitinated
within and around this functional domain of the tau protein
(Morishima-Kawashima et al., 1993; Cripps et al., 2006). Here,
using CHIP (chn-1 in C. elegans) RNAi and CHIP/ mice, we
demonstrate that CHIP is essential for the in vivo degradation of
phospho-tau species, perhaps indicating that tau must first be
released from the microtubule to become a CHIP substrate. The
finding by Nishimura et al. (2004) suggests that phosphorylation
of tau within this microtubule binding domain by PAR1, the
Drosophila ortholog of the microtubule affinity regulating kinase
2 (MARK2), causes the initial release of tau from the microtu-
bule, and only then are other tau kinases able to recognize tau as
a substrate. This finding would support the notion that CHIP
specifically recognizes phospho-tau species after their release
from the microtubule (Nishimura et al., 2004).
We therefore endeavored to more thoroughly examine the
relationship between CHIP activity and tau accumulation in a
mammalian system. The present results indicate that loss of func-
tional activity of CHIP is associated with rapid accumulation of
ubiquitin-negative phospho-tau species that accumulate in the
presynaptic compartment of mice that are 25–30 d old. When
these CHIP/ mice were crossbred with mice expressing mu-
tant human tau (JNPL3), human tau was converted to a higher
molecular weight species. Dephosphorylation experiments
proved that the high molecular weight tau present in CHT and
CHIP/ mice was phosphorylated (Figs. 3D, 8), suggesting that
tau is continually and rapidly phosphorylated as a consequence of
normal neuronal plasticity. Thus, ubiquitination of phospho-tau
species by CHIP is critical to prevent their accumulation. If the
delicate balance of phospho-tau turnover is altered by impaired
proteasomal function, tau overexpression, or enhanced tau phos-
Figure 6. RNAi for CHIP and the C. elegans ortholog chn-1 promotes accumulation of abnormally phosphorylated tau in both a
mouse neuroblastoma cell line and a transgenic nematode line. An isogenic C. elegans line transgenic for tau::EGFP was generated
and fed bacteria containing a chn-1 short hairpin RNA construct. A, C, Although Tau::EGFP worms had fluorescence (A), those
receiving the chn-1 RNAi had robust increases in tau::EGFP protein in the tail region (C). The boxed areas are shown at higher
magnification in B and D, respectively. Scale bars: A, C, 100 m; B, D, 20 m. E, Western blot analyses of the worms demonstrate
increases in GFP, total tau, and pS396/S404 tau levels when exposed to chn-1 siRNA compared with tau::EGFP RNAi bacteria-fed
control worms. F, Real-time PCR demonstrated that chn1 mRNA expression was reduced by 50% in worms fed chn1 RNAi
bacteria compared with worms fed control RNAi bacteria. G, Four-well replicates of N2A cells transfected with CHIP siRNA or a
scrambled siRNA for 72 h were harvested for Western blot analyses. H, Those cells exposed to the CHIP siRNA had a more highly
significant increase in pS396/S404 tau ( p  0.0009) compared with total tau immunoreactivity ( p  0.016). Quantitation of
bands by densitometry revealed an 40 – 45% increase in pS396/S404 tau levels and an 20 –25% increase in total tau levels
in cells exposed to CHIP siRNA (gray bars) compared with scrambled siRNA (black bars). *p  0.05; **p  0.001. I, Additional
analysis demonstrated a significant 20% increase in pS396/S404 tau compared with total tau levels, suggesting selectivity of CHIP
for aberrant tau species. *p  0.05. For blots, values shown on the right are in kilodaltons. Ctrl, Control. Error bars represent SD.
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phorylation, aggregation of these hyper-
phosphorylated tau species into NFTs may
be a CHIP/chaperone-mediated protec-
tive mechanism rather than a direct route
to neuronal cell death. Indeed, the histo-
chemical analyses for human tau in CHT
mice further supports this notion, because
age-matched JNPL3 littermates already
develop pre-tangle perikaryal structures,
whereas human tau diffusely accumulates
primarily in presynaptic compartments of
JNPL3 mice when crossed onto a CHIP
null background (CHT) (Figs. 9, 10).
The hypothesis that aggregation of hy-
perphosphorylated tau in neurofibrillary
lesions may be a neuroprotective mecha-
nism was recently proposed by Santacruz
et al. (2005), who showed that repression
of mutant tau expression in an inducible
tau model, at an age when tangle pathol-
ogy is present, rescued memory deficits
and prevented additional neuronal loss.
NFTs, however, persisted and even
showed a tendency to increase, presum-
ably because of redistribution of soluble
intermediates into NFTs. Therefore, al-
though ubiquitination of phospho-tau
mediated by CHIP may target phosphory-
lated tau for proteasomal degradation, the
excess of abnormally phosphorylated sol-
uble tau in tauopathies or overexpressing
models may exceed the capacity of the pro-
teasome, with the excess ubiquitinated
phospho-tau being shifted into stable
aggregates.
In addition to interacting with HSP70
and HSP90 (Grelle et al., 2006), it was also demonstrated that
CHIP was capable of facilitating HSF-1 activity, demonstrating
the regulatory role that this protein may have in the inducible
chaperone response. Thus, because reductions in HSP70 have
been shown to facilitate caspase-3 activation (Li et al., 2000), one
could certainly argue that the deletion of CHIP could result in a
number of consequences because of the number of HSP70/
HSP90 client proteins that are also potential CHIP substrates.
Here, however, the finding that all of the phospho-tau species
examined were elevated, coupled with the fact that the classical
tau kinases such as GSK3- and MARK2 have not been identified
as HSP client proteins, suggests that the accumulation of tau in
these mice is attributable to the absence of CHIP-mediated ubiq-
uitination, not a secondary effect that is altering tau biology.
Interestingly, 50% of the CHIP/ and CHT mice were smaller
and feebler compared with CHIP / mice and JNPL3 litter-
mates of similar age, whereas the remaining 50% were indistin-
guishable from aged wild-type littermates. This difference may be
explained by allelic variations in the hybrid SvEv129/C57BL6 ge-
netic backgrounds that gave rise to either a protective factor/
variant in the unimpaired mice or a risk factor in the small mice.
Although mRNA expression analyses are ongoing to identify
which factor or factors are responsible for the dramatic differ-
ences observed in these mice, it is remarkable that only those
mice with the small phenotype demonstrated marked accu-
mulation of tau.
As discussed above briefly, the CHIP/ and CHT mice ex-
Figure 7. Caspase-3 activation is increased in CHIP / mice and is associated with increased apoptosis and elevated levels of
caspase-3-cleavage of tau. A, Mouse neuroblastoma cells were transfected with CHIP or negative control (Ctrl) siRNAs, and
homogenates were subjected to Western blot analysis. Both caspase-3 levels and its activity (measured by cleaved caspase-3
levels) were elevated in response to knockdown of CHIP expression. Tau cleaved at Asp421, a site at which caspase-3 is known to
cleave tau in humans (recognized by monoclonal antibody C3), was modestly increased in these cells as well. B, Similarly, in
CHIP / mice, both caspase-3 and cleaved caspase-3 levels were elevated compared with CHIP / littermates. Caspase-3-
cleaved tau was also elevated in CHIP / mice, demonstrating an interaction of these two proteins in this model of tau accu-
mulation. C, The cerebellar molecular layer shows neuropil immunoreactivity for C3 in CHIP / mice but not in CHIP /
littermates. D, Caspase-3 immunoreactivity in paraffin sections of CHIP / mice demonstrates many apoptotic bodies (arrows
and inset at higher magnification) in the cerebellar deep nuclei, a region with increased tau immunoreactivity in cell processes and
neuronal perikarya (see Fig. 4 D). E, TUNEL labeling shows similar profiles in other brain regions, such as the midbrain tectum.
Insets, Note that the dense and fragmented nuclear profiles (hematoxylin in D and methyl green in E) are consistent with
apoptosis in both cleaved caspase-3-immunoreactive cells and in TUNEL-labeled cells.
Figure 8. CHIP-deficient mice overexpressing a mutant form of human tau convert all hu-
man tau into a higher molecular weight species but still fail to accumulate insoluble tau species.
Whole brain was extracted from 21-d-old CHIP /, CHIP /, CHT, and JNPL3 mice (n3 per
group, 2 shown per group), and homogenates were fractionated using Sarkosyl solubilization
for SDS-PAGE and Western blot analyses. A, Membranes were probed with the following tau
antibodies: pS396/S404-tau (PHF1), total tau (Tau5), dephosphorylated at S199/S202 (Tau 1),
and human-specific total tau (E1). CHT mice had a similar tau profile to CHIP / mice in that
phospho-tau and total tau levels were elevated and dephosphorylated tau was reduced. Note
the absence of phospho-tau species in age-matched JNPL3 mice compared with CHT mice. CHT
mice probed with the human-specific total tau antibody detected similar expression levels
compared with JNPL3 mice; however, the molecular weight of tau was higher in the CHT mice,
which collapsed with alkaline phosphatase (PPase) treatment. GAPDH levels were unchanged.
B, Coimmunoprecipitation (IP) of tau, followed by immuno-probing for polyubiquitinated spe-
cies, demonstrated that the tau accumulating in the CHT mice is ubiquitin negative, whereas
age-matched JNPL3 littermates did exhibit some polyubiquitination of tau. For blots, values
shown on the right are in kilodaltons.
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hibited increased caspase-3 activity in
multiple brain regions. Increases in
caspase-3, cleaved caspase-3, as well as
caspase-3-cleaved tau were detected in
brain homogenates from these mice but
not littermate controls. Although it has
been suggested that caspase cleavage of tau
is an early event in NFT formation (Riss-
man et al., 2004), it was clearly insufficient
to lead to tangle formation of either en-
dogenous (CHIP/) or overexpressed
mutant human tau (CHT). This provides
additional evidence that ubiquitination is
a critical component for classical tau
aggregation.
Whereas it is possible that the inherent
properties of mouse tau may make it resis-
tant to filament formation, mice deficient
in Pin1, an enzyme shown to be critical for
dephosphorylation of tau, and mice engi-
neered to have increased activation of
Cdk5 both accumulate phosphorylated
endogenous mouse tau and develop argyr-
ophilic tau aggregates (Liou et al., 2003;
Noble et al., 2003). Although ubiquitin
immunoreactivity was not assessed in
either of these models, our findings of
robust phospho-tau accumulation in
CHIP/ and CHT mice without any de-
tectable argyrophilic pathology implies
that CHIP may function to relieve neurons
of potentially toxic properties of soluble
phospho-tau intermediates through facil-
itation of its degradation and/or perhaps
promotion of aggregation.
In conclusion, neither hyperphospho-
rylation nor caspase-3 cleavage of tau,
alone or in combination, are sufficient to
induce aggregation of tau in the absence of
CHIP, indicating that CHIP may function
to not only facilitate proteasomal degrada-
tion of phospho-tau species, but that NFTs
may actually be a protective mechanism of
the neuron while an intermediate(s) is the
cause of cognitive impairment and neuro-
degeneration in tauopathies. This also
demonstrates that hyperphosphorylation
and caspase-3-mediated tau cleavage are
occurring before aggregation and that per-
haps their effects on soluble tau species are
the primary neurotoxic events in the
pathogenic cascade. The CHIP/ mice
also demonstrate that tau phosphorylation
may be a much more dynamic process
than currently thought. The accumulation
of endogenous phospho-tau in the
CHIP/ mice suggests that tau phos-
phorylation is an ongoing process under
normal conditions and deletion of CHIP
results in its accumulation. Thus, wild-type mice with an intact
repertoire of degradative components are able to prevent tau
accumulation, but not aggregation, whereas the CHIP/ mice
accumulate massive amounts of nonaggregated, ubiquitin-
negative phospho-tau. Therefore, a very delicate balance must
be maintained between de novo synthesis, phosphorylation,
microtubule binding, and degradation of tau for proper neu-
ronal function. Certainly, there would be redundancies in
Figure 9. Human tau fails to form pre-tangles in JNPL3 mice on the CHIP / background. Immunohistochemistry with the
human tau-specific antibody E1 was used to compare CHT mice (bottom row) with age-matched littermate JNPL3 mice (top row).
A, B, E1 immunoreactivity was present in mossy fibers in CA3 of the hippocampus (A, B), but only JNPL3 mice had perikaryal
staining in CA3 neurons (A). C, D, In the CA1 sector of the hippocampus, both mice had neuropil staining (C, D), but only JNPL3 had
pyramidal neuronal perikaryal staining (C). E, F, Although a few neurons had perikaryal staining in CHIP / mice in the brain-
stem (F ), they were more numerous in the brainstem of JNPL3 mice (E). Neuritic staining was present in the brainstem in both
mice.
Figure 10. Presynaptic accumulation of human tau in CHT mice. A, Pontine nuclei from CHT mice immunostained for pS202/
T205 (CP13) tau shows diffuse parenchymal immunoreactivity similar to that seen in the CHIP / mice. B, There was also no
argyrophilia with Gallyas silver stain in the CHT mice, consistent with CHIP / pathology. C, Mossy fibers in the cerebellar
internal granular layer of CHT mice show immunoreactivity for human-specific tau polyclonal antibody E1. D, Electron micrograph
of the cerebellar granular layer in CHT mice fixed with glutaraldehyde and embedded in epon resin shows well preserved synaptic
vesicles (arrows), synaptic densities (double arrows), and mitochondria (M), but no abnormal tau filaments. E, Low-power
electron micrograph of the cerebellar granular layer of CHT mouse fixed in paraformaldehyde and embedded in LR White resin
shows granule cells (arrows) and glomeruli (arrowheads). The boxed area is enlarged in F. Immunoelectron microscopy of CHT
mouse with E1 and 10 nm gold particles (arrows) shows nonfilamentous tau immunoreactivity in axonal terminal of mossy fibers.
Mitochondria (M) and synaptic densities (double arrows) are not immunolabeled.
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place to compensate for the loss of one of these critical factors
involved, a phenomenon that may account for the CHIP /
mice that lack a degenerate phenotype. In summary, CHIP
reduces the accumulation of phospho-tau species within the
brain but may promote its sequestration into aggregates under
diseased conditions.
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